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Background:  A phase  III, double-blind,  randomized,  controlled  trial was  conducted  in Hong  Kong  to
evaluate  the  efﬁcacy,  safety  and  immunogenicity  of a human  rotavirus  vaccine,  RIX4414  (RotarixTM)
against  severe  rotavirus  gastroenteritis  in  children  up  to three  years  of age.
Methods: Healthy  infants  aged  6–12  weeks  were  enrolled  between  08-December-2003  and  31-August-
2005  and  received  two  oral  doses  of either  RIX4414  vaccine  (N = 1513)  or placebo  (N = 1512)  given 2
months  apart.  Vaccine  efﬁcacy  was  assessed  from  two  weeks  post-Dose  2 until  the  children  were  twoeywords:
fﬁcacy
astroenteritis
and three  years  of  age.  Anti-rotavirus  IgA  seroconversion  rate  was  calculated  pre-vaccination  and  1–2
months  post-Dose  2 using  ELISA  (cut-off  = 20 U/mL)  for  100  infants.  Safety  was  assessed  until the  children
were  two  years  of  age;  serious  adverse  events  (SAEs)  were  recorded  throughout  the  study  period.ong Kongntussusception
otavirus
afety
Results:  In children  aged  two  and  three  years  of  life,  vaccine  efﬁcacy  against  severe rotavirus
gastroenteritis  was  95.6%  (95%  CI: 73.1%–99.9%)  and 96.1%  (95%  CI: 76.5%–99.9%),  respectively.  The
seroconversion  rate  1–2  months  after  the  second  dose  of  RIX4414  was  97.5%  (95% CI:  86.8%–99.9%).
Abbreviations: ARSN, Asian Rotavirus Surveillance Network; ATP, According-to-protocol; CCID50, Cell culture infectious dose; DTPa, Diphtheria-tetanus-acellular pertussis;
TPw,  Diphtheria-tetanus-whole cell pertussis; ELISA, Enzyme-linked immunosorbent assay; GMCs, Geometric mean concentrations; Hib, Haemophilus inﬂuenzae type b;
CD,  International Classiﬁcation of Diseases; IPV, Inactivated polio vaccine; OPV, Oral polio vaccine; RT-PCR, Reverse transcriptase polymerase chain reaction; RVGE, Rotavirus
astroenteritis; SAE, Serious adverse event; U/mL, Units per milliliter; WHO, World Health Organization.
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At least  one  SAE  was  recorded  in  439  and  477  infants  who  were  administered  RIX4414  and  placebo,
respectively  (p-value  = 0.130).  Six  intussusception  cases  were reported  (RIX4414  = 4;  placebo  =  2)  and
none  was  assessed  to be  vaccine-related.
Conclusion:  RIX4414  was  efﬁcacious,  immunogenic  and  safe  in the  prevention  of rotavirus  gastroenteritis
for at  least  two  years  post-vaccination  in  Hong  Kong  children.
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In 2008, diarrhea attributable to rotavirus infection was
stimated to have resulted in 453,000 deaths worldwide (95%
I: 420,000–494,000) in children aged less than 5 years [1].  An
stimated 41% (188,000) of these deaths occurred in the Asian
egion [1].  The World Health Organization (WHO) recommends
hat rotavirus vaccines should be used in all countries, and
onsidered a priority especially in countries with high rotavirus-
elated mortality [2].
Rotavirus is prevalent throughout Asia and is an important cause
f gastroenteritis requiring hospitalization and medical care in
hildren aged less than 5 years [3].  Data derived through passive
urveillance of rotavirus underestimated the disease burden in
ong Kong [4] and highlighted the need for active rotavirus
urveillance [5]. The ﬁrst phase of the Asian Rotavirus Surveillance
etwork (ARSN) conducted across: China, Hong Kong, Indonesia,
alaysia, Myanmar, South Korea, Taiwan, Thailand and Vietnam
etween 2001–2003 [3,5], showed that rotavirus accounted for
0–55% of hospitalization in children aged less than 5 years with
he lowest rotavirus-positivity rate (30%) recorded in Hong Kong
3].
In 2006, two new rotavirus vaccines, RIX4414 (RotarixTM;
laxoSmithKline, Belgium) and (RotateqTM; Merck Vaccines)
ecame available [1].  In studies undertaken in the Americas and
urope, both were reported to be highly efﬁcacious and were not
ssociated with any safety concerns in children during the ﬁrst two
ears of life [6–9].
This three-year study was conducted in high-income regions
f Southeast and East Asia (Singapore, Hong Kong and Taiwan) to
valuate the efﬁcacy, safety and immunogenicity of the RIX4414
accine. The overall efﬁcacy results have been previously presented
lsewhere [10,11] and this publication describes speciﬁc data
ertaining to the efﬁcacy, safety and immunogenicity of RIX4414
accine in a pediatric population in Hong Kong.
. Materials and methods
.1. Study design and infants
This phase III, randomized, double-blind, placebo-controlled
tudy (NCT00197210) was conducted at eight public hospitals
n Hong Kong. The study protocol and related documents were
pproved by the ethics committee of the individual study
enters and the study was conducted in accordance with Good
linical Practice guidelines. Parents or legal guardians of the
articipating infants provided written consent before any study-
elated procedure was undertaken.
Healthy infants 6–12 weeks of age were equally randomized
1:1 blocking scheme) to receive two doses of either RIX4414
accine/placebo at 2 and 4 months of age.
Participants received a combined diphtheria-tetanus-
cellular pertussis [DTPa], inactivated poliovirus [IPV] and
aemophilus inﬂuenzae type b [Hib] vaccine (InfanrixTM IPV/Hib;
laxoSmithKline, Belgium) concomitantly with the study vaccines
ccording to the local vaccination schedules. Alternatively, if
equested, participants could receive diphtheria-tetanus-whole© 2013 Elsevier Ltd. 
cell pertussis [DTPw], and oral poliovirus vaccine [OPV] at Maternal
and Child Health Centres for routine vaccination. According to
Hong Kong government policy, infants received a birth dose of
Bacillus Calmette-Guérin, hepatitis B and OPV vaccines. Two
weeks lapsed between the administration of any OPV dose and the
RIX4414 vaccine/placebo; the second and third doses of hepatitis
B vaccines were administered at 1 and 6 months of age. Infants
were ineligible to participate if they had previously received any
investigational drug/vaccine 30 days before the study, had allergy
to any of the vaccine components, or were immunosuppressed or
had a history of chronic gastrointestinal disease.
2.2. Study objectives and end points
The ﬁrst co-primary objective of this study was to evaluate
the efﬁcacy of the RIX4414 vaccine against severe rotavirus
gastroenteritis from two  weeks after the second vaccine dose until
two years of age. The second co-primary objective was to assess
the safety of the vaccine with regard to occurrence of deﬁnite
intussusception within 31-days following each vaccine dose.
2.3. Vaccine
Each dose of the lyophilized formulation of RIX4414 (RotarixTM,
GlaxoSmithKline, Belgium) vaccine contained at least 106.0 median
cell culture infectious dose (CCID50) of live, attenuated human
G1P[8] rotavirus. The placebo had the same constituents and
appearance as the active vaccine but without the vaccine viral
strain. Both, the RIX4414 vaccine and placebo were reconstituted
in a calcium carbonate buffer before oral administration. RIX4414
vaccine lot numbers RVC018A42, RVC019A43 and RVC021A44
were used. Lot numbers DD05A003A, DD05A003B and DD05A003C
were used for the calcium carbonate buffer and RVC020A41PL was
used for placebo.
2.4. Assessment of efﬁcacy
The surveillance for gastroenteritis episodes started from the
ﬁrst dose of RIX4414 vaccine/placebo and continued until the
children were three years of age. A gastroenteritis episode was
deﬁned as the occurrence of diarrhea [three or more, looser
than normal stools within a day] with or without vomiting.
If there was  an interval of ﬁve or more symptom-free days
between the two  gastroenteritis episodes, they were considered
as two different episodes. Hospital/medical facility surveillance
ensured that all gastroenteritis cases requiring hospitalization
and/or re-hydration therapy (equivalent to WHO  plan B [oral re-
hydration therapy for children with some dehydration in a medical
facility] or C [intravenous re-hydration for severe dehydration in
a medical facility]) [12] were recorded. Study personnel accessed
computerized admission databases in the study centers on a
daily basis to determine whether any study participants had been
admitted to public hospitals. In addition, study personnel contacted
Open access under CC BY-NC-ND license.families by telephone at least every month to determine any
admissions to private hospitals.
For each qualifying episode of gastroenteritis, parents/guardians
of infants completed a gastroenteritis diary card every day until
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wo days after the gastroenteritis symptoms had ceased. Diarrheal
tool samples were collected as soon as possible (within 7 days)
fter hospitalization for the treatment of dehydration. The severity
f the gastroenteritis episodes was assessed using a 20-Point
esikari Scale where a score of ≥11 was considered to be severe
13].
Stool samples were stored between −20 ◦C and −70 ◦C
ntil transported to GlaxoSmithKline Biologicals laboratory
here they were analyzed for rotavirus using enzyme-linked
mmunosorbent assay (ELISA; RotaCloneTM assay, Meridian
iosciences, USA). Rotavirus-positive stool samples were
ubsequently transported to Delft Diagnostic Laboratory,
he Netherlands (where they were stored at 4 ◦C) and tested
sing reverse transcriptase polymerase chain reaction (RT-PCR)
ollowed by reverse hybridization to determine the G and P types
14].
.5. Assessment of safety
Vaccine safety was assessed with respect to serious adverse
vents (SAEs), intussusception cases, hospitalizations and deaths
tarting from Dose 1 until the children were two  years of
ge. Although safety was not an endpoint during the follow-
p period between Year 2 and Year 3, investigators were
sked to report any unusual or vaccine-related SAEs during this
eriod.
.6. Assessment of immunogenicity
Blood samples from a subset of 100 infants were collected
efore vaccination and one to two months post-Dose 2 of RIX4414
accine/placebo. All children were invited to participate in the
mmunogenicity subset, and the ﬁrst 100 infants with parental
onsent had blood taken to measure the serum anti-rotavirus IgA
ntibody concentrations using an in-house ELISA [15]; cut-off was
0 Units per milliliter (U/mL).
.7. Statistical analyses
All statistical analyses were performed using SAS 8.2 (SAS
nstitute Inc., USA) and 95% Conﬁdence Interval (CI) was  calculated
sing Proc StatXact-5 (Cytel Software Corporation, USA).
The details of the sample size calculation have been previously
resented [10,11].
Primary vaccine efﬁcacy analysis was performed from two
eeks post-Dose 2 until two years of age. Secondary vaccine
fﬁcacy analysis was performed from two weeks post-Dose 2
ntil three years of age. Both vaccine efﬁcacy analyses were
erformed on the according-to-protocol (ATP) efﬁcacy cohort
ith 95% CI. The ATP efﬁcacy cohort included infants who
ad received two doses of RIX4414 vaccine/placebo, who  had
ntered the efﬁcacy follow-up period and who  had no rotavirus
ther than the vaccine strain in their gastroenteritis stool
amples. Estimates of vaccine efﬁcacy against severe rotavirus
astroenteritis caused by wild-type rotavirus, against rotavirus
astroenteritis requiring hospitalization and against all-cause
evere gastroenteritis were calculated during the period starting
rom two weeks post-Dose 2 until two and three years of age,
espectively.
One to two months post-Dose 2 of RIX4414 vaccine/placebo,
he anti-rotavirus IgA antibody seroconversion rate (anti-rotavirus
gA antibody concentration ≥20 U/mL in infants previously
eronegative) and corresponding geometric mean concentrations
GMCs) were measured with 95% CI estimated. (2013) 2253– 2259 2255
3. Results
3.1. Demography
A total of 3025 infants (RIX4414 = 1513; placebo = 1512) were
enrolled in Hong Kong between 08-December-2003 and 31-
August-2005 and were followed until three years of age for vaccine
efﬁcacy. The ATP cohort for efﬁcacy at the two- and three-year
follow-up periods included 2993 infants. The reasons for excluding
subjects from the analyses are presented in Fig. 1. There was
no difference between the treatment groups with respect to age,
gender and race. The mean age of infants was 11.6 weeks (standard
deviation [SD]: 2.37) at Dose 1 and 17.8 weeks (SD: 1.53) at Dose 2
of RIX4414/placebo.
According to Hong Kong’s routine immunization schedule,
the majority of infants (99.8%) in the RIX4414 and placebo
groups received a birth dose of OPV before Dose 1 of RIX4414
vaccine/placebo. Only one infant received OPV between Doses 1
and 2 of the RIX4414 vaccine. All other infants in the RIX4414 and
placebo groups received DTPa-IPV-Hib concomitantly with both
doses of RIX4414 vaccine/placebo.
3.2. Vaccine efﬁcacy
Vaccine efﬁcacy for severe rotavirus gastroenteritis was 95.6%
(95% CI: 73.1%–99.9%) up until two  years of age (Table 1). Vaccine
efﬁcacy against rotavirus gastroenteritis requiring hospitalization
was 91.3% (95% CI: 64.7%–99.0%) while vaccine efﬁcacy against
gastroenteritis due to any etiology requiring hospitalization was
36.8% (95% CI: 12.5%–54.6%) in the ﬁrst two  years of life (Table 1).
Similar efﬁcacy results were obtained during the follow-up period
until three years of age (Table 1).
The cumulative incidence of severe rotavirus gastroenteritis
during the ﬁrst two  years of life was  0.1% (1/1494) among RIX4414
recipients and 1.5% (23/1499) among placebo recipients; the
difference was  statistically signiﬁcant (p-value < 0.001). Similar
results for cumulative incidence during the ﬁrst three years of life
are shown in (Table 1).
The RV types isolated during severe rotavirus gastroenteritis
episodes up until three years of age were wild-type G1P[8]
(placebo = 10), G3P[8] (RIX4414 = 1; placebo = 11) and G9P[8]
(placebo = 3).
3.3. Safety
No case of intussusception was  reported within the 31-days
following each vaccine dose. Six cases of intussusception were
reported in the follow-up period until two  years of age; four
cases in the RIX4414 group and two  cases in the placebo group.
All these cases occurred between 2 and 19 months after the
second dose of RIX4414 vaccine/placebo. Five of the children
(RIX4414 = 3; placebo = 2) underwent surgery (laparotomy) and
one in the RIX4414 group underwent an air enema procedure
for the reduction of intussusception. No case was  considered
by the investigator to be vaccine-related and all the infants
recovered within two months (range: 2–37 days). No further case of
intussusception was reported during the Year 3 follow-up period.
No death was reported throughout the study.
In the follow-up period from Dose 1 until two years of age, at
least one SAE was  recorded in 439 infants in the RIX4414 group and
477 infants in the placebo group (p-value = 0.130) (data not shown).
Based on the discharge diagnosis International Classiﬁcation
of Diseases (ICD) codes, gastroenteritis-related symptoms that
required hospitalization at least once were recorded in 119 RIX4414
infants and 147 infants in the placebo group (Table 2).
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Table 1
Efﬁcacy of RIX4414 from two weeks post-Dose 2 until two  and three years of age (ATP cohort for efﬁcacy).
Gastroenteritis type RIX4414 Placebo Vaccine efﬁcacy % (95% CI) p-valued
Na nb %b (95% CI)c Na nb %b (95% CI)c
Severe rotavirus
gastroenteritis from two
weeks post-Dose 2 until
three years of age
1494 1 0.1 (0.0–0.4) 1499 26 1.7 (1.1–2.5) 96.1 (76.5–99.9) <0.001
Severe  rotavirus
gastroenteritis from two
weeks post-Dose 2 until
two  years of age
1494 1 0.1 (0.0–0.4) 1499 23 1.5 (1.0–2.3) 95.6 (73.1–99.9) <0.001
Severe  rotavirus
gastroenteritis from two
weeks post-Dose 2 until
Year 1
1494 0 0.0 (0.0–0.2) 1499 8 0.5 (0.2–1.0) 100.0 (41.2–100.0) 0.008
Severe  rotavirus
gastroenteritis from Year
1–Year 2
1494 1 0.1 (0.0–0.4) 1498 15 1.0 (0.6–1.6) 93.3 (56.6–99.8) <0.001
Severe  rotavirus
gastroenteritis from Year
2–Year 3
1461 0 0.0 (0.0–0.3) 1464 3 0.2 (0.0–0.6) 100.0 (<0.0–100.0) 0.250
Severe  rotavirus
gastroenteritis from two
weeks post-Dose 2 until
three years of age
G1 1494 0 0.0 (0.0–0.2) 1499 11 0.7 (0.4–1.3) 100.0 (60.0–100.0) <0.001
G3e,f 1494 1 0.1 (0.0–0.4) 1499 13 0.9 (0.5–1.5) 92.3 (48.6–99.8) 0.002
G9  1494 0 0.0 (0.0–0.2) 1499 4 0.3 (0.1–0.7) 100.0 (<0.0–100.0) 0.125
Hospitalization due to
rotavirus gastroenteritis
from two weeks post-Dose
2 until three years of age
1494 2 0.1 (0.0–0.5) 1499 27 1.8 (1.2–2.6) 92.6 (70.4–99.1) <0.001
Hospitalization due to
rotavirus gastroenteritis
from two weeks post-Dose
2 until two years of age
1494 2 0.1 (0.0–0.5) 1499 23 1.5 (1.0–2.3) 91.3 (64.7–99.0) <0.001
Hospitalization due to
rotavirus gastroenteritis
from two weeks post-Dose
2 until Year 1
1494 0 0.0 (0.0–0.2) 1499 8 0.5 (0.2–1.0) 100.0 (41.2–100.0) 0.008
Hospitalization due to
rotavirus gastroenteritis
from Year 1-Year 2
1494 2 0.1 (0.0–0.5) 1498 15 1.0 (0.6–1.6) 86.6 (42.5–98.5) 0.002
Hospitalization due to
rotavirus gastroenteritis
from Year 2–Year 3
1461 0 0.0 (0.0–0.3) 1464 4 0.3 (0.1–0.7) 100.0 (<0.0–100.0) 0.125
Hospitalization due to
gastroenteritis of any cause
from two weeks post-Dose
2 until three years of age
1494 83 5.6 (4.4–6.8) 1499 119* 7.9 (6.6–9.4) 30.0 (6.6–47.8) 0.011
Hospitalization due to
gastroenteritis of any cause
from two weeks post-Dose
2 until two years of age
1494 63 4.2 (3.3–5.4) 1499 100* 6.7 (5.5–8.1) 36.8 (12.5–54.6) 0.004
Hospitalization due to
gastroenteritis of any cause
from two weeks post-Dose
2 until Year 1
1494 21 1.4 (0.9–2.1) 1499 44 2.9 (2.1–3.9) 52.1 (17.7–73.0) 0.005
Hospitalization due to
gastroenteritis of any cause
from Year 1–Year 2
1494 42 2.8 (2.0–3.8) 1498 59 3.9 (3.0–5.1) 28.6 (-7.8–53.1) 0.105
Hospitalization due to
gastroenteritis of any cause
from Year 2–Year 3
1461 20 1.4 (0.8–2.1) 1464 21 1.4 (0.9–2.2) 4.6 (<0.0–50.9) 1.000
a N = number of infants included in each group.
b n/% = number/percentage of infants recording at least one severe rotavirus gastroenteritis episode/rotavirus gastroenteritis requiring hospitalization or severe
gastroenteritis regardless of any cause in each group.
c 95% CI = 95% conﬁdence interval.
d p-value = two-sided Fisher’s exact test (signiﬁcant level of  ˛ = 0.05).
e One infant from the placebo group counted in G1 and G3 categories since both RV strains were isolated.
f One infant from the placebo group counted in G3 and G9 categories since both RV strains were isolated.
* Number of hospitalizations did not represent the sum of hospitalizations from the individual years because a subject might have reported a gastroenteritis episode
requiring hospitalization in each year; however, only the ﬁrst gastroenteritis episode requiring hospitalization was  considered in the combined year follow-up.
Y.-L. Lau et al. / Vaccine 31 (2013) 2253– 2259 2257
Tot al enro lled inf ants (Tot al  vaccinat ed cohort)
(N = 3025)
RIX4414 group (N = 1513) Placebo group (N = 1512)
ATP cohort for  efficacy from 
2 weeks post-Dose 2 up to 
one years of age (N = 1494)
ATP cohort for  efficacy from 
2 weeks post-Dose 2 up to 
one years of age (N = 1499)
Protoco l forbidden vaccine 
administered = 2
Randomi zation code  bro ken * =  6
At least one study vaccine not 
administered = 11
Protoco l forbidden vaccine 
administered = 2
Randomi zation code  bro ken * =  3
At least one  study vaccine not 
administered = 7
Rotavi rus posi tiv e (other  than 
vaccine strain)  from Dose 1 till 2 
weeks post-Dose 2 = 1
ATP cohort for  efficacy from 
Year 1 to Year 2 (N = 1494)
ATP cohort for  efficacy from 
Year 1 to Year 2 (N = 1498)
Subjects who  did not enter into the 
surveillanc e peri od  of th e second 
efficacy follow-up period = 0
Subjects who  did not enter into the 
surveillanc e peri od  of th e second 
efficacy follow-up period = 1
Subjects who  did not enter into the 
surveillanc e peri od  of th e third 
efficacy follow-up period = 33
Subjects who  did not enter into the 
surveill anc e peri od  of th e third 
efficacy follow-up period = 34
ATP cohort for  efficacy from 
Year 2 to Year 3 (N = 1461)
ATP cohort for  efficacy from 
Year 2 to Year 3 (N = 1464)
Fig. 1. CONSORT ﬂowchart.
Footnotes: * The randomization code was broken for the following reasons: Kawasaki disease (RIX4414 = 2; Placebo = 2); Non-fatal SAEs—Constipation (Placebo = 1), anorexia
(RIX4414 = 1), poor weight gain (RIX4414 = 1), rash (RIX4414 = 1) and gastroenteritis (RIX4414 = 1).
Table 2
Gastroenteritis-related serious adverse events recorded from Dose 1 up to two years of age.
RIX4414 Na = 1513 Placebo Na = 1512 Difference
(RIX4414 minus
Placebo)
p-value
nb per 10,000 (95% CI)c nb per 10,000 (95% CI) Value (95% CI)
Diarrhea 2 13.2 (1.6–47.7) 3 19.8 (4.1–57.9) −6.6 (−46.4 to −30.3) 0.654
Hemorrhagic diarrhea 1 6.6 (0.2–36.8) 0 0.0 (0.0–24.4) 6.6 (−18.7 to −37.3) 0.317
Enteritis 3 19.8 (4.1–57.8) 2 13.2 (1.6–47.7) 6.6 (−30.3 to −46.3) 0.655
Frequent bowel movements 1 6.6 (0.2–36.8) 0 0.0 (0.0–24.4) 6.6 (−18.7 to −37.3) 0.317
Infectious diarrhea 1 6.6 (0.2–36.8) 0 0.0 (24.4–6.6) 6.6 (−18.7 to −37.3) 0.317
Campylobacter intestinal infection 0 0.0 (0.0–24.4) 2 13.2 (1.6–47.7) −13.2 (−48.1 to −12.1) 0.157
Salmonella gastroenteritis 19 125.6 (75.8–195.4) 25 165.3 (107.3–243.1) −39.8 (−130 to −47.5) 0.361
Shigella gastroenteritis 1 6.6 (0.2–36.8) 0 0.0 (0.0–24.4) 6.6 (−18.7 to −37.3) 0.317
Bacterial gastroenteritis (unspeciﬁed) 2 13.2 (1.6–47.7) 0 0.0 (0.0–24.4) 13.2 (−12.1–48.1) 0.157
Caliciviral gastroenteritis 6 39.7 (14.6–86.1) 7 46.3 (18.6–95.2) −6.6 (−60.3 to −45.5) 0.780
Norwalk virus 1 6.6 (0.2–36.8) 0 0.0 (0.0–24.4) 6.6 (−18.7 to −37.3) 0.317
Viral  gastroenteritis (unspeciﬁed) 3 19.8 (4.1–57.8) 7 46.3 (18.6–95.2) −26.5 (−77.7 to −17.4) 0.205
Dehydration 1 6.6 (0.2–36.8) 3 19.8 (4.1–57.9) −13.2 (−52.3 to −19.2) 0.317
Food  poisoning 0 0.0 (0.0–24.4) 1 6.6 (0.2–36.8) −6.6 (−37.4 to −18.7) 0.317
Gastritis 7 46.3 (18.6–95.1) 9 59.5 (27.3–112.7) −13.3 (−71.9 to −42.9) 0.615
Vomiting 2 13.2 (1.6–47.7) 2 13.2 (1.6–47.7) −0.0 (−36.2 to −36.2) 0.999
Miscellaneous gastrointestinal symptoms 70 462.7 (362.4–581.0) 90 595.2 (481.3–726.6) −133 (−295–27.2) 0.103
At  least one symptom 119 – 147 – – –
a N = number of subjects having received at least one dose.
b n = number of subjects reporting at least once the speciﬁed SAE.
c 95% CI = 95% conﬁdence interval.
Note:  The gastroenteritis-related symptoms reported at least once were based on discharge diagnosis ICD codes.
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Eight vaccine-related SAEs, all occurring after the ﬁrst vaccine
ose, were recorded (six in the RIX4414 group and two  in the
lacebo group). They comprised rash (RIX4414 = 1), gastroenteritis
RIX4414 = 3; placebo = 1), constipation (placebo = 1), anorexia
RIX4414 = 1) and poor weight gain with frequent bowel movement
RIX4414 = 1). All infants, except the one with constipation, were
ospitalized for these SAEs and all recovered.
.4. Immunogenicity
One to two months post-Dose 2, the anti-rotavirus IgA antibody
eroconversion rate in the subset of 100 infants was 97.5% (95%
I: 86.8%–99.9%) in the RIX4414 group, with a GMC  of 314.6 U/mL
95% CI: 215.1–460.1). None of the infants in the placebo group
eroconverted for anti-rotavirus IgA antibodies and the GMCs in
his group were below 20 U/mL.
. Discussion
This was the ﬁrst study to report detailed efﬁcacy, safety
nd immunogenicity data for the RIX4414 vaccine speciﬁcally in
hildren from Hong Kong. Further data on rotavirus and all-cause
astroenteritis may  be useful in making informed decisions on the
se of rotavirus vaccination in this setting.
The results established that the RIX4414 vaccine provided high
nd sustained protection against severe rotavirus gastroenteritis
aused by wild-type rotavirus strains particularly during the
rst two years of life (vaccine efﬁcacy = 95.6%). Although
ossible protection was observed during the third year (vaccine
fﬁcacy = 96.1%), the group difference did not reach statistical
igniﬁcance. The efﬁcacy of the RIX4414 shown in this study was
omparable to that observed in two-year efﬁcacy studies conducted
n Latin America (vaccine efﬁcacy = 80.5% [95% CI: 71.3%–87.1%])
nd Europe (vaccine efﬁcacy = 90.4% [95% CI: 85.1%–94.1%]) [8,9].
RIX4414 vaccine had an acceptable safety proﬁle. As anticipated,
he number of infants who reported gastroenteritis-related
ymptoms at least once in the placebo group (n = 147) was  higher
han that in the RIX4414 group (n = 119). There were no clinical
r statistical differences between the groups from Dose 1 up to
hree years of age with respect to gastroenteritis symptoms or
tiologies (Table 2) except for rotavirus gastroenteritis, which was
igniﬁcantly lower in the vaccine group (Table 1). Additionally,
one of the six intussusception cases (RIX4414 = 4; placebo = 2)
eported here were vaccine-related. The vaccine’s immunogenicity
as demonstrated by the high anti-rotavirus IgA seroconversion
ate (97.5%) in the subset of 100 infants one to two months post-
ose 2. The fact that no seroconversion was found in the placebo
roup when tested between approximately 4 and 6 months of age
ndicated that natural rotavirus infection in early infancy was  quite
ncommon in Hong Kong.
Consistent with a previous report from Hong Kong, G1 and
3 were the most prevalent circulating rotavirus strains followed
y G9 in children [3].  However, unlike previously, we did not
bserve the circulating G2 rotavirus strain in this study [3].  RIX4414
emonstrated efﬁcacy against the three circulating rotavirus
trains (92.3–100%).
ARSN data for Hong Kong reported that approximately one-third
f all diarrhea-related hospital admissions were due to rotavirus
5], with signiﬁcant health care and societal costs [16]. An economic
valuation using a Markov model and 2002 cost assumptions
stimated that the introduction of routine rotavirus vaccination at a
ost of US$40–$92 per course could be potentially cost-saving from
 government perspective alone [17]. In this study, the percentage
f hospitalization due to severe rotavirus gastroenteritis in the ﬁrst
hree years of life was 1.7% (26/1499 or 1 in 58) in the placebo (2013) 2253– 2259
recipients and 0.1% (1/1494) in the RIX4414 recipients. In contrast,
the previous ARSN surveillance data estimated a 2.4% (1 in 41)
cumulative risk of a rotavirus-associated admission by three years
of age and 4.2% (1 in 24) by ﬁve years of age [5].  The present data
could reduce previous estimates of the potential economic beneﬁt
of vaccination [17], although, the previous economic evaluation
did not take into account vaccine efﬁcacy against hospitalization
due to diarrhea of any etiology (30% in the ﬁrst three years
of life, preventing 2.3 admissions per 100 children vaccinated
or 1 in 43). It is also possible that vaccination could prevent
nosocomial infections [18]. Furthermore, vaccinating infants
against rotavirus provides indirect protection to unvaccinated older
children and adults through reduced transmission of the virus in the
community resulting in fewer infections in the population [19]. This
ampliﬁes the economic beneﬁt of rotavirus vaccination by reducing
rotavirus-related hospitalization costs in older age groups who  are
ineligible for rotavirus vaccination [19,20].
This study had some limitations. First, while it was possible
to routinely capture all admissions to public hospitals via a
computerized system in this trial, admissions to private hospitals
might have been missed or notiﬁed late. Although such cases
should have been recorded in the diary cards maintained by
parents, the retrospectively obtained information could be less
complete and stool samples might not have been collected. This
limitation could contribute to the apparent low rotavirus admission
rates and vaccine efﬁcacy against all-cause diarrhea. Second, this
study was not powered to draw more deﬁnitive conclusions
on the potential beneﬁts of introducing rotavirus vaccines in
Hong Kong. Nevertheless, substantial reductions in rotavirus-
associated hospitalization rates have been observed following
universal rotavirus vaccination in both developed countries
(Australia [20,21], Austria [22], Belgium [23,24], United States
[25]) and developing countries (Brazil [26,27], El Salvador [28,29],
Mexico [30], Nicaragua [31], Panama [32]). In addition, Brazil and
Mexico have witnessed reductions in all-cause mortality from
gastroenteritis following the introduction of rotavirus vaccination
[27,33,34]. Third, although there were multiple comparisons
(without adjustment) of SAEs, calculated p-values less than 0.05
were used to highlight potential differences which would require
further attention. Therefore, statistically signiﬁcant ﬁndings should
be interpreted with caution and clinical signiﬁcance must be
considered.
5. Conclusion
The study provided speciﬁc data about rotavirus vaccination
in Hong Kong that could help public health ofﬁcials with their
consideration of universal rotavirus vaccination. There were no
safety concerns or cases of vaccine-related intussusception in this
study. Two oral doses of RIX4414 administered concomitantly with
routine childhood vaccines offered high and sustained protection
against severe rotavirus gastroenteritis caused by circulating
rotavirus strains and against all-cause gastroenteritis in Hong Kong
children during their ﬁrst two years of life and possibly extending
to their third year.
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